Managed Care
|
Keeping Pace with Targeted Therapies in Lung Cancer: Highlights from the 2006 ASCO Annual Meeting |
New for 2007–2008
The Advanced Certificate Program: Lung Cancer Management
Current and emerging strategies for treating and managing patients with small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and nonresectable lung cancers - learn more...
The Advanced Certificate Program: Lung Cancer Management
Current and emerging strategies for treating and managing patients with small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and nonresectable lung cancers - learn more...
Keeping Pace with Targeted Therapies
| |
| This timely interactive program, featuring highlights of presentations from the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO), critically examines how results from recent clinical trials with novel targeted therapies may impact the treatment of patients with non–small-cell lung cancer (NSCLC). | |
| top |
|
TARGET AUDIENCE |
|
| This activity is designed for medical directors, pharmacy directors, and nurse case managers who provide care for patients with lung cancer. | |
ACTIVITY GOAL |
|
| The goal of this CME/CE activity is to provide state-of-the-science highlights and associated information from ASCO to educate managed care audiences on innovations in targeted therapies for the treatment of lung cancer. | |
LEARNING OBJECTIVES |
|
|
|
| top | |
CME INFORMATION |
|
STATEMENT OF ACCREDITATION |
|
| Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. | |
CREDIT DESIGNATION |
|
| Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. |
|
CE INFORMATION: NURSES |
|
| This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 contact hour. Provider #00012705. | |
CE INFORMATION: PHARMACISTS |
|
 Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the live Q & A program is 052-000-06-020-L01 and the on-demand program is 052-000-06-020-H01. Either number provides 1 contact hour (0.1 CEU). |
|
|
|
| top | |
DISCLOSURE INFORMATION |
|
| The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. | |
| For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR). | |
Roy S. Herbst, MD, PhD, has received grant/research support from Amgen Inc, AstraZeneca, Eli Lilly and Company, Genentech, Inc, and Taiho; is a consultant for Amgen Inc, AstraZeneca, Eli Lilly and Company, and Genentech, Inc; and is on the speakers bureau of AstraZeneca, Eli Lilly and Company, and Genentech, Inc. Dr. Herbst has disclosed that he will reference the unlabeled/unapproved use of bevacizumab. |
|
Karen L. Kelly, MD, is on the speakers bureau of Inside Cancer and Lilly Oncology; and has received consulting fees from AstraZeneca, Bristol Myers-Squibb, Genentech, Inc, Imclone, and Lilly Oncology. Dr. Kelly has disclosed that she will reference the unlabeled/unapproved use of cetuximab and antiangiogenesis inhibitors. |
|
Michelle A. Purdom, RN, BSN, has no significant relationships to disclose. Ms. Purdom has disclosed that she will not discuss any investigational or unlabeled uses of commercial products in this activity. |
|
Peer Reviewer has disclosed no significant relationships. |
|
Projects In Knowledge's staff members have no significant relationships to disclose. |
|
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. |
|
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. |
|
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient. |
|
Click here for TECHNICAL REQUIREMENTS |
|
This independent CME activity is supported by an educational grant from Genentech, Inc. | |
| top
1774 |
|
|
|
